Comparative Pharmacology
Head-to-head clinical analysis: TRIMPEX versus XERAVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIMPEX versus XERAVA.
TRIMPEX vs XERAVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial thymidine synthesis and DNA replication.
Eravacycline is a tetracycline-class antibacterial that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from attaching to the A-site. It exhibits activity against a broad range of Gram-positive, Gram-negative, and anaerobic bacteria, including many tetracycline-resistant strains due to modifications circumventing common resistance mechanisms.
5 mg/kg orally every 6 hours for acute infections; 5 mg/kg orally every 12 hours for chronic urinary tract infections.
200 mg intravenously over 60 minutes every 12 hours
None Documented
None Documented
8-11 hours; prolonged in renal impairment (creatinine clearance <10 mL/min: 20-40 hours)
Terminal elimination half-life is approximately 42 hours (range 30-60 hours) in healthy subjects; prolonged in elderly patients and those with severe hepatic impairment.
Renal: 40-70% as unchanged drug; biliary/fecal: minimal (10-15% as metabolites)
Fecal (approximately 80-90% as unchanged drug); renal (less than 1% as unchanged drug).
Category C
Category C
Antibiotic
Antibiotic